MTCR - MTCR STOCK NEWS

Metacrine, Inc. (NASDAQ:MTCR) announced new preclinical data at Digestive Disease Week 2021, demonstrating the synergistic effects of its FXR agonist, MET642, combined with the JAK inhibitor, tofacitinib, in treating inflammatory bowel disease (IBD). This combination led to significant improvement in a murine colitis model, suggesting a possible shift in treatment approaches for IBD. Metacrine's platform aims to provide targeted, non-immunosuppressive oral therapies for IBD, enhancing treatment options. The poster presentation is scheduled for May 21, 2021.

Metacrine (NASDAQ:MTCR) announced the enrollment of 60 patients in its Phase 2a trial for MET642, aimed at treating NASH. Interim data is expected to be released in Q4 2021, following 16 weeks of treatment. The study will ultimately include 180 patients, with full topline results anticipated in H1 2022. The trial evaluates the safety and efficacy of MET642, a farnesoid X receptor agonist, which has shown promise based on earlier research.

Metacrine, Inc. (NASDAQ:MTCR) provided a clinical update and financial results for Q1 2021, highlighting notable advancements in its MET409 and MET642 programs. The topline data for MET409's Phase 2a trial, evaluating its combination with empagliflozin for treating NASH and type 2 diabetes, is now expected in Q4 2021, moving up from early 2022. Interim results for the MET642 Phase 2a trial are also scheduled for Q4 2021. Despite increased R&D expenses of $10.9 million and a net loss of $14.8 million, the company maintains a strong cash position of $84.5 million, ensuring continued development efforts.

Metacrine, a clinical-stage biopharmaceutical company focused on liver and gastrointestinal disease therapies, will present virtually at the 2021 RBC Global Healthcare Conference on May 18, 2021, at 5:25 p.m. ET. CEO Preston Klassen will lead the presentation, which can be accessed through a live webcast. The company's FXR platform underpins two product candidates: MET409 and MET642, with ongoing clinical trials targeting NASH and type 2 diabetes. Visit Metacrine's website for further details and to access the webcast replay, available for 30 days.

Metacrine, Inc. (NASDAQ:MTCR) announced the appointment of Dr. Julia C. Owens to its board of directors, effective April 1, 2021. Dr. Owens brings extensive biopharmaceutical experience, having co-founded Millendo Therapeutics and raised $195 million for its pipeline development. Metacrine is focused on liver and gastrointestinal diseases, notably its FXR programs targeting non-alcoholic steatohepatitis (NASH). The company is advancing clinical trials for its candidates MET409 and MET642, which aim to address the lack of approved treatments for NASH, a growing health concern.

Metacrine, Inc. (Nasdaq: MTCR) announced significant developments in its clinical programs and recent financial results for 2020. The company expects to report interim data from its Phase 2a trial of MET642 in patients with NASH in Q4 2021 and topline results for MET409 in combination with empagliflozin in the first half of 2022. Notably, the MET409 trial showed a 38% mean relative liver fat reduction. Metacrine's cash position stands at $96.2 million, sufficient to fund operations through 2022, despite a net loss of $37.3 million for the year.

Metacrine, Inc. (Nasdaq: MTCR) announced final results from its Phase 1 trial of MET642, an FXR agonist for non-alcoholic steatohepatitis (NASH). The trial showed sustained pharmacodynamic effects with once-daily oral dosing, no adverse increases in LDL cholesterol, or pruritus. All treatment-emergent adverse events were mild to moderate. The trial findings will be presented at the 2021 NASH-TAG Conference. Metacrine has initiated a Phase 2a trial to further investigate MET642's therapeutic potential.

Metacrine, Inc. (Nasdaq: MTCR) will hold a conference call on March 18, 2021, at 8:30 a.m. ET to discuss its Q4 and full-year 2020 financial results. The company specializes in developing therapies for liver and gastrointestinal diseases, with ongoing clinical trials for its product candidates, MET409 and MET642, aimed at treating non-alcoholic steatohepatitis (NASH). MET409 is currently in combination studies, while MET642 has completed Phase 1 trials. Interested parties can join via phone or webcast.

Metacrine, Inc. (Nasdaq: MTCR) has initiated its Phase 2a trial for MET642, targeting non-alcoholic steatohepatitis (NASH). The trial, set to last 16 weeks, will include randomized, placebo-controlled evaluations to assess the drug's safety and efficacy. MET642 is designed to offer improved therapeutic outcomes, having previously shown a promising profile in Phase 1 studies. An interim analysis is anticipated in Q4 2021, with full results expected by H1 2022. This trial marks a significant advancement in Metacrine's ongoing efforts to develop effective treatments for liver diseases.